Task Force 4: Inpatient Management of Patients with MCSD - The ...

19. Holman WL, Rayburn BK, McGiffin DC et al. Infection in ventricular assist devices: prevention
and treatment. Ann Thorac Surg. 2003;75(6 Suppl):S48-S57.
20. Darouiche RO, Wall MJ, Jr., Itani KM et al. Chlorhexidine-Alcohol versus Povidone-Iodine for
Surgical-Site Antisepsis. N Engl J Med. 2010;362(1):18-26.
21. Holman WL, Skinner JL, Waites KB, Benza RL, McGiffin DC, Kirklin JK. Infection during
circulatory support with ventricular assist devices. Ann Thorac Surg. 1999;68(2):711-716.
22. Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR. The Society of Thoracic
Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration.
Ann Thorac Surg. 2006;81(1):397-404.
23. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after
cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance.
Circulation. 2000;101(25):2916-2921.
24. Eyler RF, Butler SO, Walker PC et al. Vancomycin use during left ventricular assist device
support. Infect Control Hosp Epidemiol. 2009;30(5):484-486.
25. Engelman R, Shahian D, Shemin R et al. The Society of Thoracic Surgeons practice guideline
series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann Thorac Surg.
2007;83(4):1569-1576.
26. Perl TM. Prevention of Staphylococcus aureus infections among surgical patients: beyond
traditional perioperative prophylaxis. Surgery. 2003;134(5 Suppl):S10-S17.
27. Rose EA, Gelijns AC, Moskowitz AJ et al. Long-term use of a left ventricular assist device for
end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443.
28. Holman WL, Park SJ, Long JW et al. Infection in permanent circulatory support: experience
from the REMATCH trial. J Heart Lung Transplant. 2004;23(12):1359-1365.
29. Wilson W, Taubert KA, Gewitz M et al. Prevention of infective endocarditis: guidelines from
the American Heart Association: a guideline from the American Heart Association Rheumatic
Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in
the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and
Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.
Circulation. 2007;116(15):1736-1754.
30. Pasque MK, Hanselman T, Shelton K et al. Surgical management of Novacor drive-line exit site
infections. Ann Thorac Surg. 2002;74(4):1267-1268.
31. Zierer A, Melby SJ, Voeller RK et al. Late-onset driveline infections: the Achilles' heel of
prolonged left ventricular assist device support. Ann Thorac Surg. 2007;84(2):515-520.
32. Chinn R, Dembitsky W, Eaton L et al. Multicenter experience: prevention and management of
left ventricular assist device infections. ASAIO J. 2005;51(4):461-470.
33. Garatti A, Giuseppe B, Russo CF, Marco O, Ettore V. Drive-line exit-site infection in a patient
with axial-flow pump support: successful management using vacuum-assisted therapy. J Heart
Lung Transplant. 2007;26(9):956-959.
34. Hravnak M, George E, Kormos RL. Management of chronic left ventricular assist device
percutaneous lead insertion sites. J Heart Lung Transplant. 1993;12(5):856-863.
35. Baudouin SV, Evans TW. Nutritional support in critical care. Clin Chest Med. 2003;24(4):633-
644.
36. Holdy K, Dembitsky W, Eaton LL et al. Nutrition assessment and management of left
ventricular assist device patients. J Heart Lung Transplant. 2005;24(10):1690-1696.
37. Scurlock C, Raikhelkar J, Mechanick JI. Impact of new technologies on metabolic care in the
intensive care unit. Curr Opin Clin Nutr Metab Care. 2009;12(2):196-200.
38. Scurlock C, Raikhelkar J, Mechanick JI. Intensive metabolic support: evolution and revolution.
Endocr Pract. 2008;14(8):1047-1054.
43